Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

2,000 heart attack patients enrolled in landmark Data-Gathering study

NCT ID NCT07522164

Knowledge-focused Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is observing 2,000 people who have had a heart attack to collect detailed medical information, images, and blood samples. Researchers will use this data to better understand different types of heart attacks and find new ways to predict and prevent future heart problems. The goal is to improve personalized treatment for heart attack patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,000 people

The number who actually took part.

Started

Apr 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 2,000 adult patients diagnosed with Acute Myocardial Infarction (AMI) will be recruited from four major tertiary medical centers in Shanghai, China. The cohort will include adult patients of all genders, representing a typical Chinese AMI population. Within this overall cohort, a select subgroup of approximately 200 patients, exhibiting specific high-risk clinical phenotypes of AMI (including those with vulnerable plaques, Myocardial Infarction with Non-obstructive Coronary Arteries \[MINOCA\], and borderline coronary lesions), will undergo deeper clinical and molecular phenotyping. This is an observational cohort study.

Ages

14 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with Acute Myocardial Infarction (AMI), regardless of age or gender. * Patients willing and able to provide informed consent. Patients identified to be part of specific high-risk AMI subgroups (for deep phenotyping), including: * AMI patients with high-risk vulnerable plaques (e.g., thin-cap fibroatheroma, large lipid core) identified by intracoronary imaging (OCT/NIRS). * AMI patients with non-obstructive coronary arteries (coronary stenosis \<50% on angiography) and diagnosis confirmed by cardiac MRI (MINOCA). * AMI patients with borderline coronary lesions (50%-80% stenosis on angiography or CTA) requiring functional assessment (e.g., FFR/QFR/IVUS). Exclusion Criteria: * Presence of severe non-cardiovascular comorbidities that would limit participation or confound study results. * Inability or unwillingness to comply with long-term follow-up requirements. * Patients who refuse to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction

Contacts and locations

Locations

  • Zhongshan Hospital, Fudan University

    Shanghai, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.